How we isolated the TRK oncogene

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

I was very surprised to see in an issue of the NEJM earlier this year that Loxo Oncology had developed a selective TRK inhibitor, larotrectinib, and even more surprised to learn that TRK fusions occur in about 1 percent of all human cancers.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Mariano Barbacid
AXA-CNIO Professor of Molecular Oncology, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid

YOU MAY BE INTERESTED IN

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
Harold P. Freeman, a surgeon who started his career in Harlem, where, in addition to performing surgeries, he pioneered the system of patient navigation, and who studied health disparities and served as president of the American Cancer Society and chair of the President’s Cancer Panel, died on Aug. 11. He was 93.
Mariano Barbacid
AXA-CNIO Professor of Molecular Oncology, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login